Opdivo Approved in Europe for Additional Use in Melanoma Patients

Opdivo Approved in Europe for Additional Use in Melanoma Patients

Source: 
CP Wire
snippet: 
  • Approval makes Opdivo the only PD-1 with EC approval in adjucant setting
  • The indication is for both BRAF mutant and wild-type melanoma
  • Approval based on superior results vs Yervoy in Ph III trial